Literature DB >> 12592350

Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.

P Meeus, H Demuynck, Ph Martiat, L Michaux, E Wouters, A Hagemeijer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12592350     DOI： 10.1038/sj.leu.2402791

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.

Authors:  Monika Ribeiro de Mello Conchon; Israel Bendit; Patricia Ferreira; Walter Lima; Cristina Kumeda; Lucia Dias; Dalton de Alencar Fischer Chamone; Pedro Enrique Dorlhiac-Llacer
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

2.  Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.

Authors:  Jae-Sook Ahn; Yeo-Kyeoung Kim; Se Ryeon Lee; Li Yu; Deok-Hwan Yang; Sang-Hee Cho; Hyun Jeong Shim; Woo Kyun Bae; Je-Jung Lee; Ik-Joo Chung; Myung Gun Shin; Hyeoung-Joon Kim
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

3.  Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.

Authors:  Arturo Vega-Ruiz; Susan O'Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; Hagop Kantarjian; Farhad Ravandi
Journal:  Leuk Res       Date:  2008-03-19       Impact factor: 3.156

4.  t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.

Authors:  Marija Denčić-Fekete; Vesna Đorđević; Clelia Tiziana Storlazzi; Gradimir Janković; Andrija Bogdanović; Jelica Jovanović; Mariano Rocchi; Biljana Todorić-Živanović; Milica Strnad; Mirjana Gotić
Journal:  Int J Hematol       Date:  2009-03-26       Impact factor: 2.490

5.  Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Authors:  Peter Valent; Thomas Lion; Dominik Wolf; Christian Sillaber; Hermine Agis; Andreas Petzer; Alois Lang; Peter Kalhs; Dietmar Geissler; Richard Greil; Werner Linkesch; Sonja Burgstaller; Josef Thaler; Günther Gastl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  A progenitor cell origin of myeloid malignancies.

Authors:  Hiroshi Haeno; Ross L Levine; D Gary Gilliland; Franziska Michor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-21       Impact factor: 11.205

7.  Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report.

Authors:  Majd D Jawad; Ronald S Go; Rhett P Ketterling; Kebede H Begna; Kaaren K Reichard; Min Shi
Journal:  Clin Case Rep       Date:  2016-02-08

8.  [Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].

Authors:  J Wang; Yanli Zhang; J Zhou; Y L Zu; Z Li; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.